Wird geladen...
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
BACKGROUND: Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months. Because it also modulates the immune system, both beneficially and negatively, understanding how TMZ interacts with immunotherapeutics is i...
Gespeichert in:
| Veröffentlicht in: | J Immunother Cancer |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Publishing Group
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7252967/ https://ncbi.nlm.nih.gov/pubmed/32457126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000345 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|